Incanthera PLC (AQSE:INC) has filed two trademark names for the commercial use of its skin cancer formulation, currently identified as Sol.
The specialist dermatology company said it filed UK trademark applications to register the signs ACTINOMOD and ACTINODERM on Tuesday and Wednesday last week.
The applications will now be examined by the UK trade marks office (UKIPO).
Incanthera said this was in line with the ongoing progression of its commercialisation goals for its innovative skin cancer technology formulation.
Meanwhile, management were said to be continuing to make positive progress on discussions with two global companies for the potential licence of its formulation for the treatment of actinic keratosis and prevention of skin cancer.
Chairman Tim McCarthy said: “As our licencing discussions progress, the filing of these two trademark names will allow us to look at various branding and marketing opportunities in readiness for next steps.
“We continue to make good progress in discussions with our two prioritised partners."